NCT00113763 - Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

463

Participants

Timeline

Start Date

January 1, 2004

Primary Completion Date

October 1, 2008

Study Completion Date

June 1, 2009

Conditions

Colorectal CancerMetastases

Interventions

OTHER

Best supportive care

Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).

DRUG

Panitumumab

Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.